BeiGene ends pact with Shoreline, its ‘entry into cell therapy’

BeiGene said its four-target natural killer cell therapy collaboration with Shoreline Biosciences is over. And by reneging on Shoreline’s iPSC-NK cell technology, BeiGene loses its “entry into cell therapy,” a phrase used to describe the tie-up in an investor presentation last year.

BeiGene, which reported that…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks